Physician profile
Michael Diffendall
NPI 1184667057
$979.67
in general payments reported to CMS, 2019-2025
10 companies · $269 in 2025
The $269 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $10.16 · 2022: $129 · 2023: $460 · 2024: $111 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $840.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $236.37 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $135.82 | 2022-2025 | Total30, Precision 1 |
| Lkc Technologies, INC. | $128.68 | 2023 | |
| Johnson & Johnson Vision Care, INC. | $118.20 | 2022-2025 | Acuvue |
| Oyster Point Pharma, INC. | $107.22 | 2023 | Tyrvaya |
| Coopervision INC. | $90.06 | 2022-2025 | Myday Contact Lens |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.36 | 2022-2023 | Xifaxan |
| Bausch & Lomb Americas INC. | $63.89 | 2022-2023 | Infuse |
| Sun Pharmaceutical Industries INC. | $12.91 | 2023 | Cequa |
| Oasis Medical, INC. | $10.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Diffendall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.